La cadena de opciones muestra datos clave de las opciones de acciones de Aytu BioPharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Aytu BioPharma..

Aytu BioPharma (NASDAQ:AYTU) Bolsa, Cadena de Opciones

Aytu BioPharma

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Inc

TRC's offer is currently scheduled to expire one minute after 11:59 p.m., New York City time, on March 24, 2025. TRC may extend the offer, or subject to the conditions of the offer, terminate it, before the expiration date.
The offer represents less than 0.01% of Microsoft's outstanding common stock.

News

MSFT

Microsoft Expresses No Opinion And Is Neutral On TRC's Mini-Tender Offer For Up To 300,000 Shares At $391.00 Per Share In Cash

VICI Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>) has outperformed the market over the past 5 years by 1.51% on an annualized basis producing an average annual return of 21.42%. Currently, VICI Props has a market capitalization of $34.32 billion. 
Buying $100 In VICI: If an investor had bought $100 of VICI stock 5 years ago, it would be worth $282.77 today based on a price of $32.49 for VICI at the time of writing.
<h3>VICI Props's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742249731_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

VICI

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

The re-election of Maxime Lombardini, Jules Niel, Pierre-Emmanuel Durand, María Teresa Arnal, Bruce Churchill, Blanca Treviño de Vega and Justine Dimovic as members of the Board., and election of Maxime Lombardini as Chair of the Board. Tomas Eliasson has decided not to seek re-election.

Management

TIGO

Millicom Nomination Committee Proposes Election Of Pierre-Alain Allemand As New Member Of Board

Buybacks

FINV

FinVolution Plans Repurchase Up To $150M Worth Of Its Shares During The Period From March 20, 2025 To March 19, 2027

The dividend is expected to be distributed on or around May 7, 2025 to shareholders of record as of the close of business on April 16, 2025.

Dividends

FinVolution Approves Cash Dividend Increase To $0.277 Per ADS, Which Represents Payout Ratio Of Approximately 21.5%

Each ADS of the Company represents five Class A ordinary shares of the Company.

Earnings

FinVolution Group Q4 Adj EPADS $0.38, Net Revenue $473.6M

Chinese equities are on track to deliver their strongest quarterly performance relative to the S&amp;P 500 in nearly 15 years, as investors rotate out of overvalued U.S. stocks into battered Chinese shares, betting on <a href="https://www.benzinga.com/topic/china">a policy-driven recovery.</a>
The iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) has surged 26.6% year-to-date through March 17 close, heading for its best quarterly performance since early 2009. Meanwhile, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) is down 3.2% year-to-date, pushing Chinese stocks' relative outperformance to nearly 30%, the widest margin since mid-2007.
Value Partners Group expressed optimism about the Chinese equity market, stating in an email Monday that "the China A-share market is close to the bottom. Valuations are low, and so are market expectations, which means downside risk is limited." 
The firm anticipates an upward market trend in 2024, albeit with volatility due to uncertainties surrounding Trump-related tariffs, geopolitics and China's domestic policy focus on demand versus supply-side measures.
<h1 class="wp-block-heading">Chart: Chinese Stocks Outshine S&amp;P 500 In Best Quarter Since 2007</h1>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17162512/image-140-1024x529.png" alt="" class="wp-image-828125" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17162512/image-140-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17162512/image-140-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17162512/image-140-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17162512/image-140-1536x793.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17162512/image-140.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h1 class="wp-block-heading">China's Policy Push To Stimulate Consumption</h1>
On Sunday, China&#8217;s State Council announced a &#8220;special action plan&#8221; to boost domestic consumption. The initiative includes policies aimed at raising incomes, expanding social safety nets, improving product quality and lifting purchase restrictions to spur spending.
Goldman Sachs' economist Yuting Yang acknowledged the direction of the stimulus but emphasized that "both funding and implementation matter for the effectiveness of China&#8217;s consumption stimulus." 
China has struggled with weak consumer confidence, exacerbated by a troubled real estate sector and sluggish labor demand. 
&#8220;Stabilizing property prices, improving labor demand and establishing a better social safety net are necessary to improve household income and facilitate a more sustainable consumption recovery,&#8221; Yang added.
<h1 class="wp-block-heading">Tech Giants Lead The Market Surge</h1>
Alibaba Group Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) soared 4.6% on Monday, extending its year-to-date rally to a staggering 74%. 
Meanwhile, Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) surged over 9% after unveiling Ernie X1, its latest AI model. The company claims Ernie X1 delivers performance comparable to DeepSeek's AI at half the cost, reinforcing China&#8217;s AI ambitions in the global tech race.
For now, the numbers tell a compelling story: Chinese equities are mounting an extraordinary comeback, outpacing U.S. stocks at a rate not seen since 2007. Whether this rally is a temporary repricing or the start of a longer-term trend depends on Beijing's ability to sustain economic growth and investor confidence.
Read Now: 
<ul>
<li><a href="http://benzinga.com/government/regulations/25/03/44364688/feds-march-meeting-expected-to-signal-no-hurry-on-rate-cuts-as-powell-likely-to-tread-carefully">Fed&#8217;s March Meeting Expected To Signal No Hurry On Rate Cuts As Powell &#8216;Likely To Tread Carefully&#8217;</a></li>
</ul>
Photo: Shutterstock

Asia

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Global

Econ #s

Economics

Tech

ETFs

BABA

BIDU

Chinese Stocks Poised For Best Quarter Vs. S&P 500 Since 2007 As Investors Bet On Policy Turnaround

Offerings

Hyatt Hotels Prices Public Offering Of $500M Of Senior Notes Due 2028

In the last three months, 17 analysts have published ratings on Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Autodesk and provided 12-month price targets. The average target is $347.18, accompanied by a high estimate of $400.00 and a low estimate of $285.00. This current average has increased by 3.42% from the previous average price target of $335.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1742248871_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Autodesk. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$315.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$365.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$350.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>William Jellison</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$285.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$335.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Steve Koenig</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$360.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$336.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$385.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$340.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$339.00</td>
<td>$361.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$325.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$345.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Michael Funk</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$335.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$357.00</td>
<td>$311.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$360.00</td>
<td>$340.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Autodesk. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Autodesk compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Autodesk's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADSK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Autodesk analyst ratings.</a>
<h2>All You Need to Know About Autodesk</h2>
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction; product design and manufacturing; and media and entertainment. Autodesk software enables design, modeling, and rendering needs of these industries. The company has over 4 million paid subscribers across 180 countries.
<h3>Autodesk's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Autodesk displayed positive results in 3 months. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 11.57%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Autodesk's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.49% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Autodesk's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.57% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Autodesk's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.89%, the company showcases efficient use of assets and strong financial health.
Debt Management: Autodesk's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.98, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ADSK

Deep Dive Into Autodesk Stock: Analyst Perspectives (17 Ratings)

Jim Carter and Dan Sheets have informed the Board of their decision not to seek re-election and to retire at the end of their terms following the Annual Meeting.
&nbsp;

CLMT

Calumet Reveals Intention To Nominate Julio Quintana And Karen Narwold To Board; Wasserstein Debt Opportunities Expresses Support

Cognizant Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $88.62, a high estimate of $103.00, and a low estimate of $80.00. This current average has increased by 4.11% from the previous average price target of $85.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1742248858_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Cognizant Tech Solns. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$88.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$93.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$94.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Kevin Mcveigh</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$86.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cognizant Tech Solns. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Cognizant Tech Solns compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Cognizant Tech Solns's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Cognizant Tech Solns's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CTSH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cognizant Tech Solns analyst ratings.</a>
<h2>All You Need to Know About Cognizant Tech Solns</h2>
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 350,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
<h3>Breaking Down Cognizant Tech Solns's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Cognizant Tech Solns's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.81% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Cognizant Tech Solns's net margin excels beyond industry benchmarks, reaching 10.74%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cognizant Tech Solns's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.78%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.72%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.1, Cognizant Tech Solns adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTSH

Deep Dive Into Cognizant Tech Solns Stock: Analyst Perspectives (8 Ratings)

During the last three months, 4 analysts shared their evaluations of Veritex Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBTX#NASDAQ">VBTX</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $32.5, a high estimate of $34.00, and a low estimate of $31.00. Experiencing a 4.41% decline, the current average is now lower than the previous average price target of $34.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1742248848_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Veritex Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Tenner</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gary Tenner</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Matt Olney</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Michael Rose</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$31.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Veritex Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veritex Holdings compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Veritex Holdings's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Veritex Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VBTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Veritex Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Veritex Holdings</h2>
Veritex Holdings Inc is engaged in the provision of commercial banking products and services to small to medium-sized businesses and professionals. The bank provides a range of banking services to individual and corporate customers, which include commercial and retail lending, and the acceptance of checking and savings deposits. It offers a suite of online banking solutions, including access to account balances, online transfers, online bill payment and electronic delivery of customer statements, as well as automated teller machines, and banking by telephone, mail and personal appointment. The company's primary sources of revenue are derived from interest and dividends earned on loans, debt and equity securities and other financial instruments.
<h3>Understanding the Numbers: Veritex Holdings's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Veritex Holdings's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -0.9%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Veritex Holdings's net margin is impressive, surpassing industry averages. With a net margin of 23.43%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Veritex Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.55%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.19%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Veritex Holdings's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VBTX

4 Analysts Assess Veritex Holdings: What You Need To Know

In the latest quarter, 11 analysts provided ratings for Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sprouts Farmers Market, revealing an average target of $169.18, a high estimate of $200.00, and a low estimate of $136.00. This current average reflects an increase of 17.49% from the previous average price target of $144.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1742248834_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Sprouts Farmers Market is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Ken Goldman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$136.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Christopher Mandeville</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$139.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$180.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$146.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$170.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Mark Carden</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$195.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sprouts Farmers Market. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sprouts Farmers Market compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sprouts Farmers Market's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SFM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sprouts Farmers Market analyst ratings.</a>
<h2>About Sprouts Farmers Market</h2>
Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.
<h3>Key Indicators: Sprouts Farmers Market's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Sprouts Farmers Market displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 17.53%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Sprouts Farmers Market's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sprouts Farmers Market's ROE excels beyond industry benchmarks, reaching 5.97%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Sprouts Farmers Market's ROA excels beyond industry benchmarks, reaching 2.2%. This signifies efficient management of assets and strong financial health.
Debt Management: Sprouts Farmers Market's debt-to-equity ratio is below the industry average at 1.27, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Sprouts Farmers Market: Insights From 11 Analyst Reviews

During the last three months, 6 analysts shared their evaluations of Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Terex, presenting an average target of $52.33, a high estimate of $59.00, and a low estimate of $45.00. Highlighting a 10.81% decrease, the current average has fallen from the previous average price target of $58.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1742248827_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Terex by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$59.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$52.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$58.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Terex. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Terex compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Terex's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Terex's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TEX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Terex analyst ratings.</a>
<h2>Get to Know Terex Better</h2>
Terex Corp is a manufacturer of materials processing machinery, waste and recycling solutions, mobile elevating work platforms (MEWPs), and equipment for the electric utility industry. The company designs builds, and supports products used in maintenance, manufacturing, energy, waste and recycling, minerals and materials management, construction, and the entertainment industry. The products are manufactured in North America, Europe, and Asia Pacific and sold all over the world. The company reports business in the following segments: (i) Materials Processing, (ii) Aerial Work Platforms, and (iii) Environmental Solutions Group.
<h3>Terex: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Terex's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.47% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Terex's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -0.16%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Terex's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.11%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Terex's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.04%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.41, Terex faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Terex Stock: Analyst Perspectives (6 Ratings)

In the preceding three months, 10 analysts have released ratings for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Ultragenyx Pharmaceutical and provided 12-month price targets. The average target is $104.8, accompanied by a high estimate of $140.00 and a low estimate of $48.00. This current average has increased by 0.96% from the previous average price target of $103.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1742248820_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Ultragenyx Pharmaceutical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allison Bratzel</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$136.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ultragenyx Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Ultragenyx Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ultragenyx Pharmaceutical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RARE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</a>
<h2>Discovering Ultragenyx Pharmaceutical: A Closer Look</h2>
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
<h3>A Deep Dive into Ultragenyx Pharmaceutical's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Ultragenyx Pharmaceutical's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 29.42%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -80.9%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -44.3%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.77%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Ultragenyx Pharmaceutical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.16.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RARE

Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews

Telix Says Brazilian Health Regulatory Agency ANVISA Has Approved Illuccix  Prostate Cancer Imaging Agent

XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.30) by 50 percent. This is a 75.94 percent increase over losses of $(1.87) per share from the same period last year. The company reported quarterly sales of $8.71 million which missed the analyst consensus estimate of $8.75 million by 0.43 percent. This is a 384.11 percent increase over sales of $1.80 million the same period last year.

Earnings Misses

XOMA

XOMA Q4 2024 GAAP EPS $(0.45) Misses $(0.30) Estimate, Sales $8.71M Miss $8.75M Estimate

Technology giant Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has been rumored to be working on foldable devices such as smartphones<a href="https://www.benzinga.com/news/24/02/36988960/foldable-apple-iphone-could-be-coming-what-investors-should-know"> for several years.</a>
A new report says the company's first foldable could be here as early as 2026.
What Happened: In the most recently reported<a href="https://www.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever"> first quarter</a>, Apple saw its iPhone revenue fall from $69.7 billion to $69.1 billion on a year-over-year basis.
Hoping for new signs of growth, Apple has launched the more affordable iPhone 16e and could have more news on the way about a foldable phone to win over investors.
GF Securities analyst Jeff Pu said Apple's first foldable is coming in 2026 and it could help the company recover from its lower-than-expected iPhone sales, as <a href="https://9to5mac.com/2025/03/17/iphone-apple-first-foldable/">reported </a>by 9to5Mac.
Pu said Apple's smartphone market will "recover in 2026" with two new foldable devices. The analyst said at least one of the devices will enter mass production in the second half of 2026 with Apple already working with suppliers.
The analyst said the foldable device "remains on track" to reach "P1" next month, an early stage of prototyping for Apple.
The report from Pu falls in line with other analysts like Ming-Chi Kuo who said the company's first foldable iPhone coming in 2026 could <a href="https://www.benzinga.com/media/25/03/44165398/apples-foldable-ai-iphone-could-cost-over-2000-20-million-units-shipped-by-2027-analyst">cost $2,000 or more.</a>
Along with a foldable iPhone, Apple is also working on a foldable device with an 18-inch screen, which would likely be a new Mac or iPad.
Read Also: <a href="https://www.benzinga.com/tech/25/02/43959549/exclusive-apple-iphone-16e-a-smart-buy-or-overpriced-heres-what-34-think">EXCLUSIVE: Apple iPhone 16e – A Smart Buy Or Overpriced? Here&#8217;s What 34% Think</a>
Why It's Important: Apple's rollout of Apple Intelligence AI features on the iPhone 16 may have underwhelmed users and led to fewer upgrades from customers.
With users waiting for more features, the question around a foldable iPhone quickly becomes whether customers are ready to pay a premium for this technology.
A foldable smartphone has been in the works for Apple for years with CEO Tim Cook speaking to engineers about a foldable iPhone back in 2018, suggesting it as a key priority for the future.
Competitors including Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>), Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google and Motorola have already released foldable phones.
While foldable smartphones make up a small percent of the overall smartphone market, Apple entering the space could serve as a true test for demand and key features available within the technology.
With chatbots becoming more predominantly used and smartphones functioning as more than just a phone, the ability to expand to a larger out-of-pocket device could become a feature consumers turn to and never look back on again.
AAPL Price Action: Apple stock was up 0.24% to $214 at market close Monday versus a 52-week trading range of $164.08 to $260.09. Apple stock is down 12.2% year-to-date in 2025 and up 23.2% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43399315/apples-better-than-feared-guidance-calms-iphone-ai-china-concerns-7-analyst-reactions">Apple&#8217;s &#8216;Better Than Feared&#8217; Guidance Calms iPhone, AI, China Concerns: 7 Analyst Reactions</a></li>
</ul>
Photo: Shutterstock

AAPL

GOOG

GOOGL

SSNLF

Apple Stock Faces Pressure From Declining iPhone Revenue: Could Company's First Foldable Smartphone In 2026 Reverse Course?

MEDIROM Healthcare Obtains New Unsecured Short-term Bank Loan Of $2.4M

Guidance

Merrill Lynch & Strategic Return Notes for Select 10 Index

Maison Solutions Reiterates 2025 Guidance For Revenues Of $120M - $125M, Net Income Positive

Press Releases

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

Contracts

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Events

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Aytu BioPharma Disclosure Notification

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Comments

Aytu BioPharma

Aytu BioPharma (AYTU) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL